Paysign(US:PAYS)2026-03-25 12:05Business Strategy and Market Position - Paysign reported a focus on corporate incentive and expense prepaid card products across various market verticals, including healthcare and loyalty rewards[166]. - The company plans to invest additional funds in technology improvements, sales and marketing, cybersecurity, fraud prevention, customer service, and regulatory compliance in 2026[169]. - Paysign's marketing strategy includes direct contact with target markets and attendance at industry-specific conferences to promote its payment solutions[168]. - Paysign's existing competitors are larger and may have greater financial resources, which could impact the company's market position[152]. Financial Performance - Total revenues for the year ended December 31, 2025, increased by $23,643,624, or 40.5%, compared to 2024, reaching $82,028,176[171]. - Pharma industry revenue surged by $21,236,219, or 167.8%, totaling $33,888,631, driven by the launch of 55 net pharma patient affordability programs[171]. - Gross profit rose by $16,519,619, or 51.3%, to $48,716,953, with a gross margin improvement to 59.4% from 55.1%[171]. - Net income for 2025 was $7,551,613, an increase of $3,735,706, or 97.9%, compared to the previous year[179]. - Adjusted EBITDA for 2025 was $19,943,694, compared to $9,621,083 in 2024, reflecting strong operational performance[183]. Cash Flow and Investments - Operating cash flow increased by $29,503,747 to $52,450,867, attributed to growth in operating assets and liabilities[188]. - Net cash used in investing activities for the year ended December 31, 2025, was $10,094,210, an increase from $9,488,702 in 2024, primarily for software licenses and fixed assets[189]. - Cash provided by financing activities for the year ended December 31, 2025, was $284,868, mainly from the exercise of options totaling $660,654, offset by the repurchase of 100,000 shares at an average price of $3.76 per share[190]. - Unrestricted cash as of December 31, 2025, was $21,067,651, an increase of $10,300,669 compared to the previous year, attributed to improved operating results[192]. - The company expects its available cash and forecasted revenues to sustain operations for the next 24 months[192]. Cardholder and Program Growth - The number of cardholders grew to approximately 8.4 million, with 670 card programs as of December 31, 2025[170]. - The company added 115 net plasma programs and launched 55 net new pharma programs during the year[170]. - Gross dollar volume loaded on cards reached $1,935 million in 2025, up from $1,783 million in 2024, indicating increased usage of prepaid card programs[180]. Revenue Recognition and Costs - Paysign's revenue is derived from cardholder fees, interchange, card program management fees, transaction claims processing fees, breakage, and settlement income[159]. - Revenue from plasma and pharma card programs includes management fees, transaction claim processing fees, and interchange fees, with revenue recognized when performance obligations are satisfied[202]. - The company recognizes breakage revenue from prepaid-stored value cards based on estimated breakage rates, utilizing third-party estimates[204]. - Cost of revenues includes transaction processing fees, data connectivity expenses, and customer service costs[206]. Tax and Stock Compensation - The effective tax rate increased to 24.7% in 2025 from 7.8% in 2024, primarily due to higher book earnings[178]. - Stock-based compensation expense is recognized for all restricted stock awards and stock options, with fair value determined using the Black-Scholes model[207]. Technology and Platform - The company operates a high-availability payment solutions platform that offers end-to-end technologies for transaction processing, cardholder enrollment, and account management[157]. - Paysign's architecture is known for cross-platform compatibility, flexibility, and scalability, allowing clients to leverage these advantages for cost savings[157].